Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing [0.03%]
围术期皮肤并发症的临床经济负担：一项基于活动的成本分析
Agostino Fortunato,Filippo Rumi,Massimo Zazzetta et al.
Agostino Fortunato et al.
Il futuro delle forme di distribuzione dei farmaci in regime di Servizio Sanitario Nazionale [0.03%]
药品在未来国家卫生服务体系中的分销形式的发展
Massimo Medaglia,Giuliano Buzzetti,Marco Cossolo et al.
Massimo Medaglia et al.
Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP) [0.03%]
血液透析治疗慢性肾病相关瘙痒症患者的意大利卫生资源消耗研究
Silvia Calabria,Lucio Manenti,Giulia Ronconi et al.
Silvia Calabria et al.
Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, ...
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas [0.03%]
意大利泌乳素瘤管理指南的药物经济学分析
Michele Basile,Ilaria Valentini,Roberto Attanasio et al.
Michele Basile et al.
Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or ...
Farmaci orfani in Italia: disponibilità e tempi di accesso a livello regionale [0.03%]
意大利的孤儿药：地区层面的可用性和上市时间
Maria Lucia Marino,Eva Alessi,Aurora Di Filippo et al.
Maria Lucia Marino et al.
Time to market access in Italia: durata del processo di P&R per i farmaci per le malattie rare [0.03%]
意大利罕见病药物上市前审评流程耗时分析
Andrea Marcellusi,Paola Raimondo,Carlotta Galeone et al.
Andrea Marcellusi et al.
Il bisogno insoddisfatto: definizioni, evidenze di letteratura e implicazioni per l’HTA [0.03%]
未满足的需求：定义、文献证据及卫生技术评估的含义
Claudio Jommi,Michela Meregaglia,Carmine Pinto
Claudio Jommi
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy [0.03%]
意大利HR阳性、HER2阴性、淋巴结阳性的高危早期乳腺癌患者使用阿贝西利联合内分泌治疗与单纯内分泌治疗的 cost-effectiveness 分析
Alison Davie,Sory Traoré,Massimo Giovannitti et al.
Alison Davie et al.
Background: Abemaciclib was recently approved by the European Medicines Agency in combination with adjuvant endocrine therapy (ET) for adult patients with hormone receptor positive (HR+), human epidermal growth factor rec...
Buone pratiche per lo sviluppo dei modelli di budget impact a livello regionale [0.03%]
区域预算影响模型开发的最佳实践
Andrea Marcellusi,Angela Ragonese,Andrea Marinozzi et al.
Andrea Marcellusi et al.
COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment [0.03%]
意大利药品机构的新冠肺炎应对决策定量分析
Beatrice Canali,Laura Candelora,Francesca Fiorentino et al.
Beatrice Canali et al.
Background: Since the COVID-19 pandemic has placed more attention on drugs' approval process and the importance of rapid decision-making in the healthcare sector, it is crucial to assess how time to market (TTM) of drugs ...